Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with vari… Read more
Avicanna Inc (AVCNF) - Net Assets
Latest net assets as of September 2025: $11.70 Million USD
Based on the latest financial reports, Avicanna Inc (AVCNF) has net assets worth $11.70 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.17 Million) and total liabilities ($9.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.70 Million |
| % of Total Assets | 55.28% |
| Annual Growth Rate | N/A |
| 5-Year Change | -29.97% |
| 10-Year Change | N/A |
| Growth Volatility | 1063.54 |
Avicanna Inc - Net Assets Trend (2016–2024)
This chart illustrates how Avicanna Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Avicanna Inc (2016–2024)
The table below shows the annual net assets of Avicanna Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.74 Million | +22.20% |
| 2023-12-31 | $7.97 Million | +130.50% |
| 2022-12-31 | $3.46 Million | -49.93% |
| 2021-12-31 | $6.91 Million | -50.34% |
| 2020-12-31 | $13.91 Million | -53.44% |
| 2019-12-31 | $29.88 Million | +13.25% |
| 2018-12-31 | $26.38 Million | +3036.45% |
| 2017-12-31 | $841.07K | +2925.98% |
| 2016-12-31 | $-29.76K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Avicanna Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10206032900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $104.40 Million | 4514.02% |
| Total Equity | $2.31 Million | 100.00% |
Avicanna Inc Competitors by Market Cap
The table below lists competitors of Avicanna Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Monami
KO:005360
|
$16.22 Million |
|
Llorente & Cuenca S.A.
MC:LLYC
|
$16.22 Million |
|
HCL Infosystems Limited
NSE:HCL-INSYS
|
$16.23 Million |
|
Dongbang Agro
KO:007590
|
$16.23 Million |
|
Coliseum Acquisition Corp. Class A Ordinary Share
NASDAQ:MITA
|
$16.21 Million |
|
Wanted Lab Inc.
KQ:376980
|
$16.21 Million |
|
Bitmine Immersion Technologies Inc
PINK:BMNR
|
$16.21 Million |
|
GUILD ESPORTS PLC LS-001
F:GU0
|
$16.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avicanna Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -112,504 to 2,312,859, a change of 2,425,363.
- Net loss of 3,617,681 reduced equity.
- New share issuances of 4,803,699 increased equity.
- Other factors increased equity by 1,239,345.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.62 Million | -156.42% |
| Share Issuances | $4.80 Million | +207.7% |
| Other Changes | $1.24 Million | +53.58% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Avicanna Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.58x to 8.39x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.04 | $0.18 | x |
| 2018-12-31 | $0.84 | $0.18 | x |
| 2019-12-31 | $1.00 | $0.18 | x |
| 2020-12-31 | $0.17 | $0.18 | x |
| 2021-12-31 | $0.02 | $0.18 | x |
| 2022-12-31 | $-0.01 | $0.18 | x |
| 2023-12-31 | $0.00 | $0.18 | x |
| 2024-12-31 | $0.02 | $0.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Avicanna Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -156.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.21%
- • Asset Turnover: 1.27x
- • Equity Multiplier: 8.70x
- Recent ROE (-156.42%) is above the historical average (-289.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-26.86K |
| 2017 | -309.08% | -9750.46% | 0.01x | 2.52x | $-2.68 Million |
| 2018 | -38.77% | -6017.63% | 0.00x | 1.54x | $-8.93 Million |
| 2019 | -94.12% | -12524.06% | 0.00x | 2.02x | $-23.31 Million |
| 2020 | -546.23% | -2093.02% | 0.05x | 5.01x | $-33.46 Million |
| 2021 | -1463.51% | -513.15% | 0.15x | 19.46x | $-16.89 Million |
| 2022 | 0.00% | -364.02% | 0.23x | 0.00x | $-14.70 Million |
| 2023 | 0.00% | -52.07% | 0.76x | 0.00x | $-8.73 Million |
| 2024 | -156.42% | -14.21% | 1.27x | 8.70x | $-3.85 Million |
Industry Comparison
This section compares Avicanna Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avicanna Inc (AVCNF) | $11.70 Million | 0.00% | 0.81x | $16.21 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |